Radiopharm Specialist Navidea Steps Up Licensing Activity, Opens Boston Office In Anticipation Of Key Approval Decision
This article was originally published in The Pink Sheet Daily
In the past year, Navidea has struck two licensing deals, expanded its geographic footprint, filed for its lead candidate Lymphoseek in the U.S. and has plans to file in Europe, and refocused into a commercial-ready biopharma specializing in radiopharmaceutical diagnostic products.
You may also be interested in...
Under CMS’ current policy for PET scans, new imaging agents approved by FDA would have to go through a national coverage analysis before Medicare will pay for them.
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.